-transparent.png){kind=logo}
Two patients without prior histories of neurologic disorders experienced generalized seizures while receiving high-dose busulfan (total dose 16 mg/kg) as part of a preparative regimen for allogeneic bone marrow transplantation. A review of the literature revealed 14 similar occurrences. Maintenance of therapeutic blood concentrations of phenytoin in subsequent patients at our institution has resulted in no further patients experiencing generalized seizures. Prophylactic anticonvulsant therapy should be considered in patients receiving high doses of busulfan.
Related Publications
C P Murphy, and
E A Harden, and
J M Thompson
May 1991,
Bone marrow transplantation,
C P Murphy, and
E A Harden, and
J M Thompson
September 1989,
Annals of internal medicine,
C P Murphy, and
E A Harden, and
J M Thompson
December 2008,
Pharmacotherapy,
C P Murphy, and
E A Harden, and
J M Thompson
January 1989,
Cancer chemotherapy and pharmacology,
C P Murphy, and
E A Harden, and
J M Thompson
August 2000,
Therapeutic drug monitoring,
C P Murphy, and
E A Harden, and
J M Thompson
July 1983,
Archives of neurology,
C P Murphy, and
E A Harden, and
J M Thompson
September 1995,
Neurology,
C P Murphy, and
E A Harden, and
J M Thompson
March 2024,
The neurologist,
C P Murphy, and
E A Harden, and
J M Thompson
January 1989,
Bone marrow transplantation,
C P Murphy, and
E A Harden, and
J M Thompson
January 1987,
Annals of internal medicine,
